@article{MTMT:31594638,
	title = {Detection of silent cerebral microcirculatory abnormalities in patients with manifest ischemic coronary disease: a perfusion brain MRI study combined with dipyridamole stress},
	url = {https://m2.mtmt.hu/api/publication/31594638},
	author = {Molnár, Tihamér and Horváth, Andrea and Molnárné Szabó, Zsuzsanna and Vámos, Zoltán and Dóczi, Tamás Péter and Illés, Zsolt László},
	doi = {10.1080/14017431.2020.1821911},
	journal-iso = {SCAND CARDIOVASC J},
	journal = {SCANDINAVIAN CARDIOVASCULAR JOURNAL},
	volume = {55},
	unique-id = {31594638},
	issn = {1401-7431},
	year = {2021},
	eissn = {1651-2006},
	pages = {97-101},
	orcid-numbers = {Horváth, Andrea/0000-0002-0396-2446; Illés, Zsolt László/0000-0001-9655-0450}
}

@article{MTMT:31076668,
	title = {Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression},
	url = {https://m2.mtmt.hu/api/publication/31076668},
	author = {Barajas, Ramon F. and Hamilton, Bronwyn E. and Schwartz, Daniel and McConnell, Heather L. and Pettersson, David R. and Horváth, Andrea and Szidonya, Laszlo and Varallyay, Csanad G. and Firkins, Jenny and Jaboin, Jerry J. and Kubicky, Charlotte D. and Raslan, Ahmed M. and Dogan, Aclan and Cetas, Justin S. and Ciporen, Jeremy and Han, Seunggu J. and Ambady, Prakash and Muldoon, Leslie L. and Woltjer, Randy and Rooney, William D. and Neuwelt, Edward A.},
	doi = {10.1093/neuonc/noy160},
	journal-iso = {NEURO-ONCOLOGY},
	journal = {NEURO-ONCOLOGY},
	volume = {21},
	unique-id = {31076668},
	issn = {1522-8517},
	abstract = {Background Noninvasively differentiating therapy-induced pseudoprogression from recurrent disease in patients with glioblastoma is prospectively difficult due to the current lack of a biologically specific imaging metric. Ferumoxytol iron oxide nanoparticle MRI contrast characterizes innate immunity mediated neuroinflammation; therefore, we hypothesized that combined ferumoxytol and gadolinium enhanced MRI could serve as a biomarker of glioblastoma pseudoprogression.Methods In this institutional review board-approved, retrospective study, we analyzed ferumoxytol and gadolinium contrast enhanced T1-weighted 3T MRI in 45 patients with glioblastoma over multiple clinical timepoints. Isocitrate dehydrogenase 1 (IDH-1) mutational status was characterized by exome sequencing. Sum of products diameter measurements were calculated according to Response Assessment in Neuro-Oncology criteria from both gadolinium and ferumoxytol enhanced sequences. Enhancement mismatch was calculated as the natural log of the ferumoxytol to gadolinium sum of products diameter ratio. Analysis of variance and Student's t-test assessed differences in mismatch ratios. P-value <0.05 indicated statistical significance.Results With the development of pseudoprogression we observed a significantly elevated mismatch ratio compared with disease recurrence (P < 0.01) within IDH-1 wild type patients. Patients with IDH-1 mutation demonstrated significantly reduced mismatch ratio with the development of pseudoprogression compared with disease recurrence (P < 0.01). Receiver operator curve analysis demonstrated 100% sensitivity and specificity for the use of mismatch ratios as a diagnostic biomarker of pseudoprogression.Conclusion Our study suggests that ferumoxytol to gadolinium contrast mismatch ratios are an MRI biomarker for the diagnosis of pseudoprogression in patients with glioblastoma. This may be due to the unique characterization of therapy-induced neuroinflammation.},
	keywords = {MACROPHAGE; glioblastoma; Ferumoxytol; Pseudoprogression; RANO},
	year = {2019},
	eissn = {1523-5866},
	pages = {517-526},
	orcid-numbers = {Horváth, Andrea/0000-0002-0396-2446}
}

@article{MTMT:3339994,
	title = {Cuprizone Administration Alters the Iron Metabolism in the Mouse Model of Multiple Sclerosis},
	url = {https://m2.mtmt.hu/api/publication/3339994},
	author = {Varga, Edit and Pandur, Edina and Ábrahám, Hajnalka and Horváth, Andrea and Ács, Péter and Komoly, Sámuel and Miseta, Attila János and Sipos, Katalin},
	doi = {10.1007/s10571-018-0578-5},
	journal-iso = {CELL MOL NEUROBIOL},
	journal = {CELLULAR AND MOLECULAR NEUROBIOLOGY},
	volume = {38},
	unique-id = {3339994},
	issn = {0272-4340},
	abstract = {Cuprizone (CZ) is a widely used copper chelating agent to develop non-autoimmune animal model of multiple sclerosis, characterized by demyelination of the corpus callosum (CC) and other brain regions. The exact mechanisms of CZ action are still arguable, but it seems that the only affected cells are the mature oligodendrocytes, possibly via metabolic disturbances caused by copper deficiency. During the pathogenesis of multiple sclerosis, high amount of deposited iron can be found throughout the demyelinated areas of the brain in the form of extracellular iron deposits and intracellularly accumulated iron in microglia. In the present study, we used the accepted experimental model of 0.2% CZ-containing diet with standard iron concentration to induce demyelination in the brain of C57BL/6 mice. Our aim was to examine the changes of iron homeostasis in the CC and as a part of the systemic iron regulation, in the liver. Our data showed that CZ treatment changed the iron metabolism of both tissues; however, it had more impact on the liver. Besides the alterations in the expressions of iron storage and import proteins, we detected reduced serum iron concentration and iron stores in the liver, together with elevated hepcidin levels and feasible disturbances in the Fe-S cluster biosynthesis. Our results revealed that the CZ-containing diet influences the systemic iron metabolism in mice, particularly the iron homeostasis of the liver. This inadequate systemic iron regulation may affect the iron homeostasis of the brain, eventually indicating a relationship among CZ treatment, iron metabolism, and neurodegeneration.},
	year = {2018},
	eissn = {1573-6830},
	pages = {1081-1097},
	orcid-numbers = {Pandur, Edina/0000-0001-5012-3242; Horváth, Andrea/0000-0002-0396-2446; Miseta, Attila János/0000-0002-7984-3347; Sipos, Katalin/0000-0002-6706-2682}
}

@article{MTMT:3325672,
	title = {Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.},
	url = {https://m2.mtmt.hu/api/publication/3325672},
	author = {Varallyay, CG and Nesbit, E and Horváth, Andrea and Várallyay, Péter and Fu, R and Gahramanov, S and Muldoon, LL and Li, X and Rooney, WD and Neuwelt, EA},
	doi = {10.1002/jmri.25943},
	journal-iso = {JMRI - J MAGN RESON IM},
	journal = {JOURNAL OF MAGNETIC RESONANCE IMAGING},
	volume = {48},
	unique-id = {3325672},
	issn = {1053-1807},
	abstract = {BACKGROUND: Cerebral blood volume (CBV) mapping with a dynamic susceptibility contrast (DSC) perfusion technique has become a clinical tool in diagnosing and follow-up of brain tumors. Ferumoxytol, a long-circulating iron oxide nanoparticle, has been tested for CBV mapping, but the optimal dose has not been established. PURPOSE: To compare ferumoxytol DSC of two different doses to standard of care gadoteridol by analyzing time-intensity curves and CBV maps in normal-appearing brain regions. STUDY TYPE: Retrospective. SUBJECTS: Fifty-four patients with various brain disorders. FIELD STRENGTH/SEQUENCE: 3T MRI. DSC-MRI was performed with 0.1 mmol/kg gadoteridol and 1 day later with ferumoxytol in doses of 1 or 2 mg/kg. ASSESSMENT: Signal changes during first pass, relative CBV (rCBV) in normal-appearing thalamus, putamen, and globus pallidus, and contrast-to-noise ratio (CNR) of the CBV maps were compared between gadoteridol and various doses of ferumoxytol using an automated method. To subjectively assess the quality of the CBV maps, two blinded readers also assessed visual conspicuity of the putamen. STATISTICAL TESTS: Linear mixed effect model was used for statistical comparison. RESULTS: Compared to gadoteridol, 1 mg/kg ferumoxytol showed no difference in CNR (P = 0.6505), peak DeltaR2*, and rCBV in the putamen (P = 0.2669, 0.0871) or in the thalamus (P = 0.517, 0.9787); 2 mg/kg ferumoxytol increased peak DeltaR2* as well as the CNR (P < 0.0001), but also mildly increased rCBV in putamen and globus pallidus (P = 0.0005, 0.0012). Signal intensities during first pass remained highly above the noise level, with overlapping of 95% confidence intervals with noise only in 3 out of 162 tested regions. Compared to gadoteridol, the visual image quality showed mild improvement with 1 mg/kg (P = 0.02) and marked improvement with 2 mg/kg ferumoxytol (P < 0.0001). DATA CONCLUSION: 1 mg/kg ferumoxytol provides similar imaging results to standard gadoteridol for DSC-MRI, and 2 mg/kg has a benefit of increased CNR, but may also result in mildly increased rCBV values. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2018.},
	year = {2018},
	eissn = {1522-2586},
	pages = {441-448},
	orcid-numbers = {Horváth, Andrea/0000-0002-0396-2446}
}

@article{MTMT:3300443,
	title = {Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas},
	url = {https://m2.mtmt.hu/api/publication/3300443},
	author = {Horváth, Andrea and Varallyay, CG and Schwartz, D and Toth, GB and Netto, JP and Barajas, R and Várallyay, Péter and Szidonya, L and Firkins, J and Youngers, E and Fu, R and Ambady, P and Bogner, Péter and Neuwelt, EA},
	doi = {10.1002/mrm.27028},
	journal-iso = {MAGN RESON MED},
	journal = {MAGNETIC RESONANCE IN MEDICINE},
	volume = {80},
	unique-id = {3300443},
	issn = {0740-3194},
	abstract = {PURPOSE: Delayed ferumoxytol enhancement on T1 -weighted images appears visually similar to gadoteridol enhancement. The purpose of this study was to quantitatively compare ferumoxytol T1 enhancement to gadoteridol enhancement with an objective, semi-automated method. METHODS: 206 sets of post-gadoteridol and 24 h post-ferumoxytol T1 -weighted scans from 58 high grade glioma patients were analyzed (9 pre-chemoradiation, 111 < 90 days post-chemoradiation, 21 > 90 days post-chemoradiation, 65 post-bevacizumab scans). Enhancement volumes and signal intensities normalized to normal appearing tissue proximal to enhancement were calculated with a semi-automated method. Enhancement cube root volumes (D) and signal intensities (SI) were compared between the 2 contrast agents, and relative difference of D and SI were compared in different treatment groups with multivariate analysis. Within patient differences in D and SI before and after treatment with bevacizumab or steroid were assessed in 26 patients in each treatment group. RESULTS: When compared to gadoteridol, ferumoxytol D was 13.83% smaller and SI was 7.24% lower (P < 0.0001). The relative differences in D and SI between the 2 contrast agents were not significantly different between treatment groups (P > 0.05). Relative difference in D and SI did not change significantly in response to bevacizumab (P = 0.5234 and P = 0.2442, respectively) or to steroid (P = 0.3774, P = 0.0741) in the within patient comparison. CONCLUSION: The correlation between the 2 contrast agents' enhancement size and signal intensity and their similar behavior in response to therapy suggest that ferumoxytol can be used for revealing enhancement in high grade glioma patients. Magn Reson Med, 2017. (c) 2017 International Society for Magnetic Resonance in Medicine.},
	year = {2018},
	eissn = {1522-2594},
	pages = {224-230},
	orcid-numbers = {Horváth, Andrea/0000-0002-0396-2446}
}

@misc{MTMT:3251521,
	title = {A corpus callosumban és a májban bekövetkező vasanyagcsere változások cuprizone indukálta demielinizáció hatására egérben},
	url = {https://m2.mtmt.hu/api/publication/3251521},
	author = {Varga, Edit and Pandur, Edina and Ábrahám, H and Horváth, Andrea and Ács, P and Pap, Ramóna and Sipos, Katalin},
	unique-id = {3251521},
	year = {2017},
	orcid-numbers = {Pandur, Edina/0000-0001-5012-3242; Horváth, Andrea/0000-0002-0396-2446; Pap, Ramóna/0000-0002-3340-0102; Sipos, Katalin/0000-0002-6706-2682}
}

@article{MTMT:3216966,
	title = {Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.},
	url = {https://m2.mtmt.hu/api/publication/3216966},
	author = {Toth, GB and Varallyay, CG and Horváth, Andrea and Bashir, MR and Choyke, PL and Daldrup-Link, HE and Dósa, Edit and Finn, JP and Gahramanov, S and Harisinghani, M and Macdougall, I and Neuwelt, A and Vasanawala, SS and Ambady, P and Barajas, R and Cetas, JS and Ciporen, J and DeLoughery, TJ and Doolittle, ND and Fu, R and Grinstead, J and Guimaraes, AR and Hamilton, BE and Li, X and McConnell, HL and Muldoon, LL and Nesbit, G and Netto, JP and Petterson, D and Rooney, WD and Schwartz, D and Szidonya, L and Neuwelt, EA},
	doi = {10.1016/j.kint.2016.12.037},
	journal-iso = {KIDNEY INT},
	journal = {KIDNEY INTERNATIONAL},
	volume = {92},
	unique-id = {3216966},
	issn = {0085-2538},
	abstract = {Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.},
	year = {2017},
	eissn = {1523-1755},
	pages = {47-66},
	orcid-numbers = {Horváth, Andrea/0000-0002-0396-2446; Dósa, Edit/0000-0003-2984-2642}
}

@mastersthesis{MTMT:31798854,
	title = {Diffusion weighted imaging in the normal appearing white matter of glioma patients},
	url = {https://m2.mtmt.hu/api/publication/31798854},
	author = {Horváth, Andrea},
	unique-id = {31798854},
	year = {2016},
	orcid-numbers = {Horváth, Andrea/0000-0002-0396-2446}
}

@article{MTMT:3047088,
	title = {Age at onset and seizure frequency affect white matter diffusion coefficient in patients with mesial temporal lobe epilepsy},
	url = {https://m2.mtmt.hu/api/publication/3047088},
	author = {Nagy, Szilvia Anett and Horváth, Réka and Perlaki, Gábor and Orsi, Gergely and Barsi, Péter and John, Flóra and Horváth, Andrea and Kovács, Norbert and Bogner, Péter and Ábrahám, Hajnalka and Bóné, Beáta and Trischlerné Gyimesi, Csilla and Dóczi, Tamás Péter and Janszky, József Vladimír},
	doi = {10.1016/j.yebeh.2016.04.019},
	journal-iso = {EPILEPSY BEHAV},
	journal = {EPILEPSY & BEHAVIOR},
	volume = {61},
	unique-id = {3047088},
	issn = {1525-5050},
	year = {2016},
	eissn = {1525-5069},
	pages = {14-20},
	orcid-numbers = {Nagy, Szilvia Anett/0000-0001-6483-9209; Barsi, Péter/0000-0002-3574-9973; Horváth, Andrea/0000-0002-0396-2446; Kovács, Norbert/0000-0002-7332-9240; Janszky, József Vladimír/0000-0001-6100-832X}
}

@article{MTMT:3035474,
	title = {Comparison of gadolinium and ferumoxytol enhancement changes in response to Avastin in high grade glioma patients},
	url = {https://m2.mtmt.hu/api/publication/3035474},
	author = {Horváth, Andrea and Csanad, Varallyay and Peter, Varallyay and Daniel, Schwartz and Prakash, Ambady and Bogner, Péter and Edward, Neuwelt},
	doi = {10.1007/s13244-016-0475-8},
	journal-iso = {INSIGHTS IMAGING},
	journal = {INSIGHTS INTO IMAGING},
	volume = {7},
	unique-id = {3035474},
	issn = {1869-4101},
	year = {2016},
	eissn = {1869-4101},
	pages = {S223},
	orcid-numbers = {Horváth, Andrea/0000-0002-0396-2446}
}